UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Position in GRAIL, Inc. $GRAL

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of GRAIL, Inc. (NASDAQ:GRAL) by 16.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 66,077 shares of the company’s stock after purchasing an additional 9,094 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.15% of GRAIL worth $4,511,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Royal Bank of Canada boosted its position in shares of GRAIL by 17.7% in the 1st quarter. Royal Bank of Canada now owns 88,082 shares of the company’s stock worth $2,250,000 after purchasing an additional 13,264 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in GRAIL by 28.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock valued at $76,000 after buying an additional 623 shares in the last quarter. NewEdge Advisors LLC increased its position in GRAIL by 390.3% during the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock valued at $45,000 after buying an additional 1,401 shares in the last quarter. JPMorgan Chase & Co. raised its stake in GRAIL by 115.7% during the second quarter. JPMorgan Chase & Co. now owns 79,544 shares of the company’s stock valued at $4,090,000 after buying an additional 42,675 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in GRAIL by 104.7% during the second quarter. American Century Companies Inc. now owns 36,237 shares of the company’s stock valued at $1,863,000 after buying an additional 18,535 shares during the last quarter.

GRAIL Price Performance

NASDAQ GRAL opened at $77.48 on Thursday. The business’s fifty day moving average price is $73.18 and its 200-day moving average price is $62.26. The stock has a market capitalization of $3.46 billion, a price-to-earnings ratio of -7.95 and a beta of 3.25. GRAIL, Inc. has a 1-year low of $35.39 and a 1-year high of $118.84.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. The firm had revenue of $44.69 million for the quarter, compared to the consensus estimate of $42.39 million. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%. Equities research analysts anticipate that GRAIL, Inc. will post -10.41 EPS for the current year.

Insider Transactions at GRAIL

In other GRAIL news, CFO Aaron Freidin sold 7,900 shares of the business’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $85.01, for a total transaction of $671,579.00. Following the completion of the sale, the chief financial officer directly owned 253,083 shares in the company, valued at $21,514,585.83. The trade was a 3.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Joshua Ofman sold 5,000 shares of the company’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $85.02, for a total transaction of $425,100.00. Following the sale, the chief executive officer directly owned 397,271 shares of the company’s stock, valued at $33,775,980.42. The trade was a 1.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on GRAL shares. The Goldman Sachs Group began coverage on GRAIL in a report on Friday, June 5th. They issued a “neutral” rating and a $60.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a research note on Friday, July 17th. Wall Street Zen downgraded shares of GRAIL from a “hold” rating to a “sell” rating in a research report on Saturday, September 5th. Mizuho lifted their target price on shares of GRAIL from $58.00 to $65.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Finally, Wolfe Research initiated coverage on shares of GRAIL in a report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Five research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, GRAIL currently has an average rating of “Hold” and an average price target of $71.11.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.